Etanercept With Tacrolimus for Psoriasis

Overview

The study is designed to evaluate the efficacy of etanercept 50 mg subcutaneously (SQ) weekly plus tacrolimus 0.1% topical ointment twice daily compared to etanercept 50 mg SQ weekly plus placebo ointment twice daily.

Full Title of Study: “Double-Blind, Placebo-Controlled, Bilateral Comparison of Topical Tacrolimus 0.1% vs. Placebo Ointment as Adjunctive Therapy for Patients With Moderate to Severe Psoriasis Who Are Candidates for or Poor Responders to Etanercept Therapy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double

Detailed Description

The study is designed to evaluate the efficacy of etanercept 50 mg SQ weekly plus tacrolimus 0.1% topical ointment twice daily compared to etanercept 50 mg SQ weekly plus placebo ointment twice daily. Subjects will be either beginning etanercept therapy or already using a stable dose of etanercept when they begin to apply tacrolimus to half of their body and placebo ointment to the other half. The study is double blinded. Total duration of the study is 12 weeks.

Interventions

  • Drug: Etanercept plus tacrolimus

Clinical Trial Outcome Measures

Primary Measures

  • Target lesion scoring (on a scale of 0-12) at week 12
  • The percentage of lesions having scores of < 2 in the topical tacrolimus and vehicle-treated sites will be assessed.

Secondary Measures

  • Photography of target lesions
  • Quarter-body photography
  • Static Physician’s Global Assessment (PGA) on each side of each subject’s body

Participating in This Clinical Trial

Inclusion Criteria

  • Adults 18 years or older with moderate to severe psoriasis, who are candidates for systemic or phototherapy, with a baseline score of 6 or higher on the target lesion score, and a baseline score of 3 or higher on the Physician's Global Assessment, on each side of the body – Patients who are already on a stable dose of etanercept for at least 2 months and have the above criteria – Subjects must have target lesions on each side of the body that are at least 1.5 cm in diameter and roughly symmetrical in appearance and location Exclusion Criteria – Inability to understand consent or comply with study requirements – Pregnancy or unwillingness to use adequate birth control method – Lactation – Psoriasis plus ultraviolet A (PUVA) or systemic therapy within the past 4 weeks (other than a stable dose of Enbrel for at least 2 months) – Ultraviolet B (UVB) or topical therapy (other than over-the-counter moisturizers) within the past 2 weeks – Active tuberculosis or other opportunistic infection – Demyelinating disease – Uncontrolled congestive heart failure – Known allergy to or any contraindications to using topical tacrolimus or etanercept – Lack of insurance coverage or inability/refusal to pay out of pocket for etanercept and standard of care laboratory tests and PPD/CXR
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • University of Medicine and Dentistry of New Jersey
    • Overall Official(s)
      • Melissa Magliocco, MD, Principal Investigator, UMDNJ – RWJMS

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.